Sipai Health Technology Co, Ltd
HKEX:314
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.08
8.03
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Sipai Health Technology Co, Ltd
Other Current Liabilities
Sipai Health Technology Co, Ltd
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sipai Health Technology Co, Ltd
HKEX:314
|
Other Current Liabilities
¥500.8m
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
D
|
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
|
Other Current Liabilities
¥1.7B
|
CAGR 3-Years
41%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
LBX Pharmacy Chain JSC
SSE:603883
|
Other Current Liabilities
¥1.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Yifeng Pharmacy Chain Co Ltd
SSE:603939
|
Other Current Liabilities
¥1.3B
|
CAGR 3-Years
22%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
ShuYu Civilian Pharmacy Corp Ltd
SZSE:301017
|
Other Current Liabilities
¥219.5m
|
CAGR 3-Years
27%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Yixintang Pharmaceutical Group Co Ltd
SZSE:002727
|
Other Current Liabilities
¥680m
|
CAGR 3-Years
28%
|
CAGR 5-Years
3%
|
CAGR 10-Years
23%
|
|
Sipai Health Technology Co, Ltd
Glance View
Sipai Health Technology Co., Ltd. operates as a medical technology and health management company. The company is headquartered in Guangzhou, Guangdong and currently employs 3,269 full-time employees. The company went IPO on 2022-12-23. The Company’s businesses include Specialty Pharmacy Business, Physician Research Assistance Business and Health Insurance Services Business. Specialty Pharmacy Business includes the operation of offline specialty pharmacies and distribution of pharmaceutical products to pharmaceutical companies and other distributors. Physician Research Assistance Business mainly provides integrated services for pharmaceutical companies to assist them in producing clinical trial data that meets the relevant regulatory standards for the pharmaceutical companies to advance to the next phase of clinical or solicit approval of a treatment by the applicable regulatory body. Health Insurance Services Business provides insurance brokerage services including distribution of various health and life insurance products on behalf of insurance carriers.
See Also
What is Sipai Health Technology Co, Ltd's Other Current Liabilities?
Other Current Liabilities
500.8m
CNY
Based on the financial report for Dec 31, 2023, Sipai Health Technology Co, Ltd's Other Current Liabilities amounts to 500.8m CNY.
What is Sipai Health Technology Co, Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 3Y
25%
Over the last year, the Other Current Liabilities growth was -5%. The average annual Other Current Liabilities growth rates for Sipai Health Technology Co, Ltd have been 25% over the past three years .
You don't have any saved screeners yet
